Background: Effective and safe antiviral treatments are required to refrain the COVID-19.
Objectives: Investigate the efficacy and safety of interferon in the treatment of COVID-19.
Methods: The inclusion criteria were patients who gave their signed consent, with detection confirmed by RT-PCR of SARS-CoV-2, 18 years and older. Patients received therapy as per the Guinea COVID-19 protocol in the group B; the group A received the same treatment including administration of interferon. The outcome measures the time to negative conversion of SARS-CoV-2, mortality, patients transferred to ICU and safety, according to the reports of adverse events.
Results: 345 patients were included, 171 in the group A and 174 in the group B. After the treatments, the RT-PCR negative results were attained in the patients in the group A in 9.15±4.79 days and in those in the group B in 14.83±6.67 days. No patient in the group A had to be transferred to ICU, and they all survived; in the group B, 26 patients were transferred to ICU and six of them died. There were eight adverse events with causality relation with interferon administration.
Conclusions: The interferon resulted effective and safe in contributing to the viral replication conversion to negative results in shorter time and to survival.
Keywords: COVID 19; SARS-Cov-2; human recombinant interferon; zoonosis.
© 2023 Moya VSR et al.